Cargando…
Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895929/ https://www.ncbi.nlm.nih.gov/pubmed/36742302 http://dx.doi.org/10.3389/fimmu.2023.1115691 |
_version_ | 1784881953630060544 |
---|---|
author | Tan, Tingting Lin, Xiaotong Ling, Jing Wang, Rong Chen, Yue Cai, Longmei Sun, Jingyuan Wu, Dehua Xie, Guozhu |
author_facet | Tan, Tingting Lin, Xiaotong Ling, Jing Wang, Rong Chen, Yue Cai, Longmei Sun, Jingyuan Wu, Dehua Xie, Guozhu |
author_sort | Tan, Tingting |
collection | PubMed |
description | Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited high response rate compared with single-agent sunitinib. However, whether the patients with primary resistance to PD-1 blockade could benefit from the addition of lenvatinib is still unclear. Herein, we reported a patient with mRCC who was primary resistant to pembrolizumab and achieved a durable complete response after a short-term treatment with lenvatinib. This case report indicates that the patients with primary resistance to anti-PD-1 therapy could benefit from the short-term lenvatinib in combination with anti-PD-1 therapy, and provides a useful paradigm worthy of establishing a clinical trial for mRCC patients with primary resistance to anti-PD-1 therapy. |
format | Online Article Text |
id | pubmed-9895929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98959292023-02-04 Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma Tan, Tingting Lin, Xiaotong Ling, Jing Wang, Rong Chen, Yue Cai, Longmei Sun, Jingyuan Wu, Dehua Xie, Guozhu Front Immunol Immunology Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited high response rate compared with single-agent sunitinib. However, whether the patients with primary resistance to PD-1 blockade could benefit from the addition of lenvatinib is still unclear. Herein, we reported a patient with mRCC who was primary resistant to pembrolizumab and achieved a durable complete response after a short-term treatment with lenvatinib. This case report indicates that the patients with primary resistance to anti-PD-1 therapy could benefit from the short-term lenvatinib in combination with anti-PD-1 therapy, and provides a useful paradigm worthy of establishing a clinical trial for mRCC patients with primary resistance to anti-PD-1 therapy. Frontiers Media S.A. 2023-01-20 /pmc/articles/PMC9895929/ /pubmed/36742302 http://dx.doi.org/10.3389/fimmu.2023.1115691 Text en Copyright © 2023 Tan, Lin, Ling, Wang, Chen, Cai, Sun, Wu and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tan, Tingting Lin, Xiaotong Ling, Jing Wang, Rong Chen, Yue Cai, Longmei Sun, Jingyuan Wu, Dehua Xie, Guozhu Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma |
title | Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma |
title_full | Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma |
title_fullStr | Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma |
title_full_unstemmed | Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma |
title_short | Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma |
title_sort | case report: abolishing primary resistance to pd-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895929/ https://www.ncbi.nlm.nih.gov/pubmed/36742302 http://dx.doi.org/10.3389/fimmu.2023.1115691 |
work_keys_str_mv | AT tantingting casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT linxiaotong casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT lingjing casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT wangrong casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT chenyue casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT cailongmei casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT sunjingyuan casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT wudehua casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma AT xieguozhu casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma |